Haematology

News

NICE backs NHS use of Autolus' leukaemia CAR-T

Hundreds of people with an aggressive leukaemia will be able to access a CAR-T therapy developed by UK biotech Autolus after a NICE recommendation.

News

Agios shares slump on sickle cell disease data

Shares in Agios lost nearly half their value after it posted mixed clinical results from a phase 3 trial of its sickle cell disease therapy mitapivat.

News

Filmmaker helps AbbVie spread the word about leukaemia

AbbVie has turned to an award-winning documentary director to help it highlight the lives of people living with chronic lymphocytic leukaemia.

News

NICE backs Roche's non-Hodgkin lymphoma drug Columvi

NICE backs NHS use of Roche's Columvi as a second-line therapy for a form of non-Hodgkin lymphoma affecting thousands of people in the UK each year.

News

GSK's Blenrep's back in US, but with a narrower label

Against the odds, GSK has secured FDA approval for its multiple myeloma therapy Blenrep, three years after it was removed from sale.

News

Ipsen buys ImCheck, adding mid-stage leukaemia drug

Ipsen has agreed to buy ImCheck and its anti-BTN3A antibody for acute myeloid leukaemia in a deal that could be worth up to €1bn.

NICE backs NHS use of Autolus' leukaemia CAR-T

Agios shares slump on sickle cell disease data

Filmmaker helps AbbVie spread the word about leukaemia

NICE backs Roche's non-Hodgkin lymphoma drug Columvi

GSK's Blenrep's back in US, but with a narrower label

Ipsen buys ImCheck, adding mid-stage leukaemia drug

LSX2026: On promise and patience, with Hans Schambye

Using AI-driven synthetic personas to take your insights fur...

Haematology

Editor's Picks